Skip to main content
Enveric Biosciences, Inc. logo

Enveric Biosciences, Inc. — Investor Relations & Filings

Ticker · ENVB ISIN · US02362F3029 US Professional, scientific and technical activities
Open in API
Filings indexed 1,028 across all filing types
Latest filing 2024-02-26 Director's Dealing
Country US United States of America
Listing US ENVB

About Enveric Biosciences, Inc.

https://www.enveric.com/

Enveric Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of neuropsychiatric disorders. The company focuses on conditions such as anxiety, depression, and addiction. Leveraging its proprietary discovery and development platform, The Psybrary™, Enveric has created a robust intellectual property portfolio of novel molecules for specific mental health indications. Its development pipeline includes candidates such as EB-003 for difficult-to-treat mental health disorders and the EVM301 series.

Recent filings

Filing Released Lang Actions
Director's Dealing 2024
Director's Dealing
2024-02-26 English
Director's Dealing 2024
Director's Dealing
2024-02-26 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 21, 2024, by Enveric Biosciences, Inc. It includes a press release about a library of preclinical compounds targeting mental health disorders. The document explicitly states it is a Current Report pursuant to the Securities Exchange Act of 1934 and includes a Regulation FD Disclosure. The length is 4330 characters, which is relatively short and the content is primarily an announcement of a press release rather than a detailed financial report or earnings release. There are no financial statements or detailed financial data included, only a reference to the press release as Exhibit 99.1. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Annual Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-02-21 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-02-14 English
Delisting Announcement 2024
Delisting Announcement Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Enveric Biosciences, Inc. It specifically addresses a notice from Nasdaq regarding the company's non-compliance with the minimum stockholders' equity requirement and the potential for delisting if compliance is not regained by specified deadlines. The key section is Item 3.01, which is titled 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.' The content focuses on the Nasdaq Staff's notification and the company's plan to regain compliance. There are no financial statements or detailed financial data presented, only a regulatory update about listing status. According to the filing definitions and rules, this type of document is classified as a Delisting Announcement (DLST). The document length (6027 characters) is sufficient to be the actual announcement, not just a brief notice or report publication announcement. Therefore, the correct classification is DLST with high confidence.
2024-02-09 English
AMENDMENT NO. 2 TO SCHEDULE 13G
Major Shareholding Notification
2024-02-06 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.